[1]https://www.fiercepharma.com/special-reports/2023-drug-approvals-after-down-year-fda-signs-bounty-new-medicines [2]https://www.prnewswire.com/news-releases/fda-approves-first-oral-treatment-for-postpartum-depression-301894037.html [3]https://www....
参考文献 [1]https://www.fiercepharma.com/special-reports/2023-drug-approvals-after-down-year-fda-signs-bounty-new-medicines [2]https://www.prnewswire.com/news-releases/fda-approves-first-oral-treatment-for-postpartum-depression-301894037.html [3]https://www.prnewswire.com/news-releases/fda-...
参考资料：[1] Satsuma Pharmaceuticals and SNBL Receive FDA Acceptance of NDAResubmission of STS101 for the Acute Treatment of Migraine With or Without Aura.Retrieved November 27, 2024 from https://www.prnewswire.com/news-releases/satsuma-pharmaceuticals-and-snbl-receive-fda-acceptance-of-nda-resubmi...
[1]https://www.fiercepharma.com/special-reports/2023-drug-approvals-after-down-year-fda-signs-bounty-new-medicines [2]https://www.prnewswire.com/news-releases/fda-approves-first-oral-treatment-for-postpartum-depression-301894037.html [3]https://www.prnewswire.com/news-releases/fda-approves-f...
[1] Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC. Retrieved December 8, 2023, from https://www.ipsen.com/press-releases/ipsen-confirms-u-s-fda-grants-priority-review-for-new-drug-application...
[1]https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2023 [2]https://www.empr.com/home/news/ryzneuta-approved-for-chemotherapy-induced-neutropenia/ [3]https://www.astrazeneca.com/media-centre/press-releases/2023...
2.https://www.prnewswire.com/news-releases/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine-301814984.html 3.https://www.prnewswire.com/news-releases/fda-approves-new-drug-to-prevent-rsv-in-babies-and-toddlers-301878799.html 4....
[6] Axsome Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for AXS-05 for Treatmentof Major Depressive Disorder. Retrieved May 25, 2022 from, https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-fda-acceptance-and...
[1] Ipsen confirms U.S. FDA grants priority review for New DrugApplication for elafibranor for the treatment of rare cholestatic liverdisease, PBC. Retrieved December 8, 2023, fromhttps://www.ipsen.com/press-releases/ipsen-confirms-u-s-fda-grants-priority-review-for-new-drug-application-for...
The latest news regarding FDA applications, processes, and approval. This section contains releases regarding the Food and Drug Administration’s consideration of new products, drugs, therapies and treatments. Find announcements covering every stage of the FDA application process, from filing to eventual...